• Press Release

Two Mount Sinai Neuroscientists Receive Prestigious Awards From the Society for Neuroscience

  • New York, NY
  • (October 28, 2020)

Ashley Lepack, PhD, a former doctoral student at the Icahn School of Medicine at Mount Sinai, and Yasmin Hurd, PhD, Director of the Addiction Institute of Mount Sinai, have received prestigious awards from the Society for Neuroscience (SfN), the world’s largest organization of brain and nervous system scientists and physicians. The awards recognize Dr. Lepack for her innovative doctoral research and Dr. Hurd for her outstanding achievements in research and for promoting the professional advancement of women in neuroscience. The awards were presented during SfN’s Award Announcement Week 2020.

“Drs. Lepack and Hurd are both outstanding scientists, with one making significant contributions to the field of neuroscience early in her career and the other being recognized for a career filled with both outstanding research achievements and dedicated action taken to help advance young scientists in the field,” said Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute at Mount Sinai, and past president of the Society for Neuroscience. “We are thrilled that SfN has recognized their excellence and commitment by choosing them as the recipients of these impressive awards. These awards underscore the world-leading neuroscience community at Mount Sinai.”

Dr. Lepack received the Nemko Prize in Cellular and Molecular Neuroscience, which recognizes young neuroscientists for a PhD thesis that advanced the understanding of molecular, genetic, or cellular mechanisms underlying higher brain function and cognition. During her thesis work at Mount Sinai, performed in the laboratories of her thesis advisor Ian Maze, PhD, Associate Professor of Neuroscience, and co-mentor, Paul Kenny, PhD, Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience, she discovered a novel role for dopamine in addiction. While dopamine is known for its role as a neurotransmitter involved in reward signaling and drug addiction, Dr. Lepack revealed its surprising role in directly modifying gene expression in response to cocaine or heroin use, dopamine is chemically added to histone proteins, altering not only gene expression, but also disrupting dopaminergic neuron functioning and triggering addictive behaviors. She also demonstrated that manipulating these modifications can alleviate the addictive behaviors in animal models. In a separate study, Dr. Lepack characterized a novel chromatin “reader” protein, called BRWD1, and discovered its role in normal brain development and in the physiological and behavioral consequences of its triplication in Down syndrome.

Dr. Lepack’s work required diverse technical skills, from analytical mass spectrometry to chemical biology and behavioral neuroscience, understanding new technologies for probing novel histone modifications, and developing unique experimental approaches and molecular and viral tools. Her transformative project translated mechanistic studies to possible therapeutic avenues and was the first to indicate a neurotransmission-independent role for dopamine. Dr. Lepack is now a scientist at BlueRock Therapeutics.

“I am so honored to have received such a prestigious award recognizing all of my hard work during the PhD training phase of my career. I would like to thank my co-mentors, Drs. Ian Maze and Paul Kenny, for all of their support, as well as the Nemko Family and Society for Neuroscience for their recognition of our work,” said Dr. Lepack.

Dr. Hurd received The Mike Salpeter Lifetime Achievement Award, which recognizes neuroscientists with outstanding achievements in research who have significantly promoted the professional advancement of women in neuroscience. Dr. Hurd has made groundbreaking advances in the understanding of how drugs of abuse alter the brain, via epigenetic and cellular mechanisms, to cause addiction. Her work has revealed the effects of exposure to drugs early in life, whether prenatally or during adolescence, and how it increases vulnerability to addiction later in life. She was a trailblazer in cannabis studies and also led the field in understanding the role of opioid peptides in drug abuse. She conducts a truly translational neuroscience program, moving her work from animal models into clinical trials.

Dr. Hurd is also a champion of underrepresented groups in science and medicine. In addition to mentoring numerous women and minority graduate students and postdoctoral fellows, she promoted the increased recruitment of women and minority candidates in the Graduate School while serving as director of the school’s MD/PhD program. Dr. Hurd was the founding director of the Diversity in Biomedical Research Committee at Mount Sinai, has been both the vice-chair and chair of the American College of Neuropsychopharmacology Minority Task Force, and sits on many boards and committees that aim to enhance diversity, equity, and inclusion. She has helped to develop outreach programs in local schools and is an ambassador for female scientists around the globe.

“I am humbled by this honor. It has been a privilege to be part of the ‘village’ of many who are trying to help young scientists find their path in this challenging, yet exciting, field,” said Dr. Hurd. “The future of science, and thus our world, is now more than ever critically dependent on expanding the diversity of young scientists who will significantly advance scientific and medical breakthroughs.”


About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.